IL-8 as A Cancer and Autoimmune Drug Target (G28340)

Target Name: IGHVIII-67-4

NCBI ID: G28340

IGHVIII-67-4

Other Name(s): 3-67.4P | immunoglobulin heavy variable (III)-67-4 (pseudogene) | IGHVIII674 | Immunoglobulin heavy variable (III)-67-4 (pseudogene)

IL-8 as A Cancer and Autoimmune Drug Target

IGHVIII-67-4 (3-67.4P), also known as human interleukin-8 (IL-8), is a cytokine that plays a crucial role in the immune response. It is produced by various immune cells in the body, including natural killer cells, T-cells, and macrophages.IL-8 is a potent chemoattractant that can recruit immune cells to sites of infection or injury, thereby contributing to the immune response.

IL-8 has been identified as a potential drug target in the treatment of various diseases, including cancer, infection, and autoimmune disorders. Its unique mechanism of action and its potential as a therapeutic agent have made it an attractive target for research and development.

IL-8 has been shown to promote the recruitment of immune cells to sites of infection or injury. WhenIL-8 is administered to cancer cells, it has been observed to increase the number of immune cells present at the cancer site, leading to an increased immune response against the cancer cells. This increase in immune activity can result in the destruction of cancer cells, making IL-8 a potentially effective cancer therapeutic.

IL-8 has also been shown to be a potent chemoattractant for cancer cells. WhenIL-8 is added to the culture medium containing cancer cells, it has been observed to significantly increase the number of cancer cells that have migration out of the culture dish and into the surrounding tissue. This increased migration of cancer cells can lead to the development of new tumors, making IL-8 a potentially dangerous cancer-promoting factor.

IL-8 has also been associated with the development of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. In these disorders, the immune system becomes hyperactive and attacks the body's own tissues, leading to inflammation and damage. By inhibiting the activity of IL-8, researchers have found potential treatments for these disorders.

IL-8 is also a potent predictor of mortality in patients with advanced cancer. High levels of IL-8 have been observed in the blood of patients who have recently passed away from various types of cancer. By identifying individuals with high IL-8 levels, researchers may be able to identify those at high risk for mortality and develop targeted therapies to improve survival.

Despite the potential benefits of IL-8 as a drug target, its high levels can also pose a risk. IL-8 has been shown to contribute to the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, high levels of IL-8 have been observed in individuals with autoimmune disorders, which may increase the risk of these disorders.

In conclusion, IL-8 is a drug target with great potential for the treatment of various diseases. Its unique mechanism of action and its potential as a therapeutic agent make it an attractive target for research and development. While its high levels can pose a risk, its potential benefits make it a valuable tool in the fight against disease.

Protein Name: Immunoglobulin Heavy Variable (III)-67-4 (pseudogene)

The "IGHVIII-67-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVIII-67-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets